Tag: ACS
TCT 2019: Apixaban plus a P2Y12 inhibitor is the optimal strategy...
A prespecified analysis of data from the AUGUSTUS study, released at late-breaking session at the Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019; 25–29 September,...